Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors

Clinical Pharmacokinetics

Volumn 52, Issue 10, 2013, Pages 815-831

  Chauvin, Benoit ^a   Drouot, Sylvain ^a   Barrail Tran, Aurélie ^a,b   Taburet, Anne Marie ^a  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATORVASTATIN; BOCEPREVIR; CERIVASTATIN; COBICISTAT; CYTOCHROME P450 3A; DARUNAVIR; ELVITEGRAVIR; EMTRICITABINE; FLUINDOSTATIN; FOSAMPRENAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MEVINOLIN; NELFINAVIR; PEGINTERFERON ALPHA; PITAVASTATIN; PRAVASTATIN; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; TELAPREVIR; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG;

ALBUMINURIA; AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; COGNITIVE DEFECT; CONFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; ISCHEMIC HEART DISEASE; LIVER INJURY; LOW DRUG DOSE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SYSTEMATIC REVIEW;

ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPATITIS C; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROTEASE INHIBITORS;

EID: 84881414412     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0075-4     Document Type: Review

References (167)

1. FDA Drug safety communication: interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. 2012. Available from http://www.fda.gov/Drugs/DrugSafety/ ucm293877.htm. Accessed 18 Apr 2013.
2. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22(6):441-57.
3. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41(5):343-70.
4. Egger SS, Ratz Bravo AE, Hess L, et al. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging. 2007;24(5):429-40.
5. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17(4):123-32.
6. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346(7):539-40.
7. EMEA. Annexe II: Scientific conclusions and grounds for withdrawal of the marketing authorisations presented by the EMEA. 2002.
8. Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy. 2000;20(9):1066-71.
9. Lewis JS II, Terriff CM, Coulston DR, et al. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin Ther. 1997;19(2):187-214.
10. Bruno R, Sacchi P, Maiocchi L, et al. Hepatotoxicity and antiretroviral therapy with protease inhibitors: a review. Dig Liver Dis. 2006;38:363-73.
11. The EuroSIDA Study Group. Changing patterns of morbidity and mortality across Europe in patients infected with HIV-1. Lancet. 1998;352:1725-30.
12. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-60.
13. Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother. 2008;61(2):238-45.
14. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74(5):1045-52.
15. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351(9119):1881-3.
16. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093-9.
17. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995;333(23):1528-33.
18. Calza L, Manfredi R, Farneti B, et al. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents. 2003;22:54-9.
19. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53(1):10-4.
20. Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012;28(10):1184-95.
21. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723-35.
22. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17(17):2479-86.
23. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104(3):257-62.
24. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37(5):613-27.
25. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
26. Program NCE. NCEP ATP III Guidelines. 2001.
27. Stein JH, Wu Y, Kawabata H, et al. Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors. Am J Cardiol. 2003;92(3):270-4.
28. EASL. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-64.
29. Chopra A, Klein PL, Drinnan T, et al. How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int. 2013;33(Suppl 1):30-4.
30. Wilby KJ, Greanya ED, Ford JA, et al. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012;11(2):179-85.
31. Ramanathan S, Mathias AA, German P, et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011;50(4):229-44.
32. PubMed Health [Internet]. Bethesda (MD): National Library of Medicine (US). http://www.ncbi.nlm.nih.gov/pubmedhealth/.
33. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed 17 April 2013.
34. European AIDS clinical society guidelines version 6.1 November 2012. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ EacsGuidelines-v6.1-2edition.pdf. Accessed 17 April 2013.
35. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 1976;72(2):323-6.
36. Rodwell VW, Nordstrom JL, Mitschelen JJ. Regulation of HMG-CoA reductase. Adv Lipid Res. 1976;14:1-74.
37. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425-30.
38. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32(5):403-25.
39. Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003;5(5):372-8.
40. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84(3):413-28.
41. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118.
42. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis. 2011;215(1):1-8.
43. Ose L, Budinski D, Hounslow N, et al. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin. 2009;25(11):2755-64.
44. Lee SH, Chung N, Kwan J, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther. 2007;29(11):2365-73.
45. Weng TC, Yang YH, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139-51.
46. Smith MEB, Lee NJ, Haney E, Carson S. Drug class review: HMG-CoA reductase inhibitors (statins) and fixed dose combination products containing a statin. Final report: update 5. 2009. Available from http://www.ncbi.nlm.nih. gov/books/NBK47273/pdf/TOC.pdf.
47. Libby P, Sukhova G, Lee RT, et al. Molecular biology of atherosclerosis. Int J Cardiol. 1997;62(Suppl 2):S23-9.
48. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med. 1990;322(23):1635-41.
49. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-39.
50. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-22.
51. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-7.
52. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207.
53. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-58.
54. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
55. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-9.
56. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349-57.
57. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-9.
58. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-59.
59. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
60. Sathasivam S, Lecky B. Statin induced myopathy. BMJ. 2008;337:a2286.
61. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788-97.
62. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403-14.
63. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29(8):1761-70.
64. Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012;23(4):317-24.
65. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001;35(9):1096-107.
66. Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 2004;13(7):417-26.
67. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565-81.
68. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97(8A):77C-81C.
69. Guedes AM, Neves PL. Statins for renal patients: a fiddler on the roof? Int J Nephrol. 2012;806872:1-8.
70. Agarwal R. Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol. 2004;15(9):2502-3.
71. Kalaitzidis RG, Elisaf MS. The role of statins in chronic kidney disease. Am J Nephrol. 2011;34(3):195-202.
72. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924-9.
73. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-42.
74. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7):800-11.
75. Tuccori M, Lapi F, Testi A, et al. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting. Drug Saf. 2008;31(12):1115-23.
76. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26-37.
77. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos. 2002;30(5):505-12.
78. Garcia MJ, Reinoso RF, Sanchez Navarro A, et al. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol. 2003;25(6):457-81.
79. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112:71-105.
80. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet. 2008;47(7):463-74.
81. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42(13):1141-60.
82. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol. 2001;57(5):357-64.
83. Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther. 2012;92(5):584-98.
84. Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther. 2003;25(10):2553-63.
85. Keskitalo JE, Zolk O, Fromm MF, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86(2):197-203.
86. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11(6):933-46.
87. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63(1):157-81.
88. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol. 2009;5(7):703-29.
89. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006;80(4):356-66.
90. Jones HM, Barton HA, Lai Y, et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug metabolism and disposition: the biological fate of chemicals. 2012;40(5):1007-17.
91. Romaine SP, Bailey KM, Hall AS, et al. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 2010;10(1):1-11.
92. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med. 2008;359(8):789-99.
93. Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006;130(6):1793-806.
94. Kopplow K, Letschert K, Konig J, et al. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005;68(4):1031-8.
95. Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos. 2007;35(5):779-86.
96. Koenen A, Kroemer HK, Grube M, et al. Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions. Expert Rev Clin Pharmacol. 2011;4(6):729-42.
97. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40(4):263-81.
98. Windass AS, Lowes S, Wang Y, et al. The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007;322(3):1221-7.
99. Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003;73(6):554-65.
100. Keskitalo JE, Pasanen MK, Neuvonen PJ, et al. Different effects of the ABCG2 c.421C > A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics. 2009;10(10):1617-24.
101. Hochman JH, Pudvah N, Qiu J, et al. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004;21(9):1686-91.
102. Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res. 2007;24(2):239-47.
103. Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs. 2010;11(3):323-32.
104. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387-402.
105. Murphy R, Pokrovskiy V, Rozenbaum W, et al. Long-term efficacy and safety of atazanavir (ATV) with stavudine (d4T) and lamivudine (3TC) in patients previously treated with nelfinavir (NFV) or ATV: 108-week results of bms study 008/044. In: 10th conference on retroviruses and opportunistic infections, Boston; 2003.
106. Martinez-Cajas JL, Wainberg MA. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res. 2007;76(3):203-21.
107. Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev. 1999;39(1-3):211-38.
108. Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther. 2005;78(6):605-18.
109. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2009;87(3):322-9.
110. Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res. 2010;85(1):190-200.
111. Shah BM, Schafer JJ, Priano J, et al. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2013. doi: 10.1002/phar.1237.
112. Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer for atazanavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients: Week 48 results. J Infect Dis 2013;PMID:23532097.
113. Permpalung N, Putcharoen O, Avihingsanon A, et al. Treatment of HIV infection with once-daily regimens. Expert Opin Pharmacother. 2012;13(16):2301-17.
114. Kis O, Robillard K, Chan GN, et al. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci. 2009;31(1):22-35.
115. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect Genet Evol. 2007;7(2):333-42.
116. Minuesa G, Huber-Ruano I, Pastor-Anglada M, et al. Drug uptake transporters in antiretroviral therapy. Pharmacol Ther. 2011;132(3):268-79.
117. Olin JL, Spooner LM, Klibanov OM. Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. Ann Pharmacother. 2012;46(12):1671-7.
118. Ferenci P, Reddy KR. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection. Antivir Ther. 2011;16(8):1187-201.
119. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-44.
120. Jacobson IM, Pawlotsky JM, Afdhal NH, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat. 2012;19(Suppl 2):1-26.
121. Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions. J Hepatol. 2012. doi: 10.1016/j.jhep.2012.10.027.
122. Hare CB, Vu MP, Grunfeld C, et al. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis. 2002;35(10):e111-2.
123. Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45(12):3445-50.
124. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16(4):569-77.
125. Granfors MT, Wang JS, Kajosaari LI, et al. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006;98(1):79-85.
126. Cheng CH, Miller C, Lowe C, et al. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm. 2002;59(8):728-30.
127. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 2002;41(14):1195-211.
128. Schmidt GA, Hoehns JD, Purcell JL, et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med. 2007;20(4):411-6.
129. FDA, Important information about interactions between certains hepatitis C drugs and cholesterol-lowering statin drugs. 2012. Available from http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm294485.htm. Accessed 18 Apr 2013.
130. Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS. 2003;17(5):207-10.
131. Product Information: LEXIVA(R) oral tablets, oral suspension, fosamprenavir calcium oral tablets, oral suspension. ViiV Healthcare and Vertex Pharmaceuticals Incorporated (per FDA), Research Triangle Park, NC. 2012.
132. Pham PA, la Porte CJ, Lee LS, et al. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother. 2009;53(10):4385-92.
133. Information Product. LIPITOR(R) oral tablets, atorvastatin calcium oral tablets. New York: Pfizer (Per FDA); 2012.
134. Information Product. PREZISTA(R) oral suspension, oral film coated tablets, darunavir oral suspension, oral film coated tablets. Titusville: Janssen Therapeutics (per manufacturer); 2012.
135. Lee JE, van Heeswijk R, Alves K, et al. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother. 2011;55(10):4569-74.
136. Product Information: VICTRELIS(R) oral capsules, boceprevir oral capsules. Merck Sharp & Dohme Corp. (per FDA), Whitehouse Station. 2012.
137. Busti AJ, Bain AM, Hall RG 2nd, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008;51(6):605-10.
138. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 1999;47(5):570-8.
139. van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther. 2007;12(7):1127-32.
140. de Kanter CT, Keuter M, van der Lee MJ, et al. Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir. Antivir Ther. 2011;16(3):435-7.
141. Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol. 1992;32(7):630-8.
142. Product Information: APTIVUS(R) oral capsules, solution, tipranavir oral capsules, solution. Boehringer Ingelheim Pharmaceuticals, Inc. (per manufacturer), Ridgefield, CT. 2012.
143. Product Information: VIRACEPT(R) oral tablets, oral powder, nelfinavir mesylate oral tablets, oral powder. ViiV Healthcare Company (Per FDA), Research Triangle Park, NC. 2012.
144. Aberg JA, Rosenkranz SL, Fichtenbaum CJ, et al. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS. 2006;20(5):725-9.
145. Aquilante CL, Kiser JJ, Anderson PL, et al. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol. 2012;52(11):1725-38.
146. Product Information: LIVALO(R) oral tablets, pitavastatin oral tablets. Kowa Pharmaceuticals America, Inc. and Lilly USA, LLC (per FDA), Montgomery, AL, 2012.
147. Pham PA, Lee L, Fuchs E, et al. Pharmacokinetic interaction between tipranavir/ritonavir and rosuvastatin (Poster 767). In: 13th Conference on Retroviruses and Opportunistic Infections. Boston, 2008.
148. Fichtenbaum CJ, Samineni D, Moore E, et al. Darunavir/ritonavir (DRV/rtv) increases rosuvastatin (RSV) concentrations but does not alter lipid-lowering effect in healthy volunteers (Abstract no. WEPE0101). In: XVIII international AIDS conference, Vienna, Austria; 2010.
149. Carr R, Andre A, Bertz R, et al. Concomitant administration of ABT-378/ritonavir (ABT-378/r) results in a clinically important pharmacokinetic (PK) interaction with atorvastatin (ATO) but not pravastatin (PRA). (Abstract 1644). In: 40th ICAAC, Toronto, Canada; 2000.
150. Wire M, Baker K, Moore K, et al. The Pharmacokinetic (PK) Interaction of GW433908 (908) with Atorvastatin (ATO) and 908/ Ritonavir (RTV) with ATO (APV10013) (abstract A-1622) 43rd ICAAC, 2003; Chicago.
151. Aslangul E, Assoumou L, Bittar R, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. Aids. 2010;24(1):77-83.
152. Bittar R, Giral P, Aslangul E, et al. Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor. Aids. 2012;26(14):1801-5.
153. Hayashi T, Yokote K, Saito Y, et al. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother. 2007;8(14):2315-27.
154. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005;59(2):239-52.
155. Fung HB, Kirschenbaum HL, Hameed R. Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000;22(5):549-72.
156. Information Product. REYATAZ(R) oral capsules, atazanavir sulfate oral capsules. Princeton: Bristol-Myers Squibb Company; 2011.
157. FDA. Consumer Health Information: FDA Expands Advice on Statin Risks. 2012 09-08 [cited 2013-01-11]; http://www.fda.gov/ForConsumers/ConsumerUpdates/ ucm293330.htm.
158. Product Information: CRIXIVAN(R) oral capsules, indinavir sulfate oral capsules. Merck Sharp & Dohme Corp. (per FDA), Whitehouse Station. 2012.
159. Information Product. KALETRA(R) film coated oral tablets, oral solution, lopinavir and ritonavir film coated oral tablets, oral solution. North Chicago: Abbott Laboratories; 2009.
160. Williams P, Muirhead G, Madigan M. Disposition and bioavailability of the HIV-proteinase inhibitor, Ro 31-8959, after single oral doses in healthy volunteers. Br J Clin Pharmacol. 1992;34:155P-6P.
161. Information Product. INVIRASE(R), saquinavir oral capsules and tablets. Nutley: Roche Laboratories Inc.; 2005.
162. Information Product. NORVIR(R) oral capsules, solution, ritonavir oral capsules, solution. North Chicago: Abbott Laboratories; 2008.
163. Product Information: STRIBILD(TM) oral tablets, elvitegravir cobicistat
164. Information Product. INCIVEK(TM) film coated oral tablets, telaprevir film coated oral tablets. Cambridge: Vertex Pharmaceuticals Incorporated; 2011.
165. Hoetelmans R, Lasure A, Koester A. The effect of TMC114, a potent next-generation HIV protease inhibitor, with low-dose ritonavir on atorvastatin pharmacokinetics (poster H-865). ICAAC, Washington, DC; 2004.
166. Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor boceprevir and the HMG-CoA reductase inhibitors atorvastatin and pravastatin. HEP DART, Koloa, Hawaii; 2011.
167. Sekar V, Spinosa-Guzman S, Marien K. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin (Abstract 55). In: 8th International Workshop on Pharmacology of HIV Therapy, 2007; Budapest.